24.85
price up icon0.65%   0.16
after-market Dopo l'orario di chiusura: 24.86 0.010 +0.04%
loading
Precedente Chiudi:
$24.69
Aprire:
$24.72
Volume 24 ore:
40.65M
Relative Volume:
0.84
Capitalizzazione di mercato:
$141.29B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
13.22
EPS:
1.8799
Flusso di cassa netto:
$12.44B
1 W Prestazione:
+1.35%
1M Prestazione:
+3.41%
6M Prestazione:
+12.75%
1 anno Prestazione:
-14.10%
Intervallo 1D:
Value
$24.60
$24.96
Intervallo di 1 settimana:
Value
$24.16
$24.96
Portata 52W:
Value
$20.91
$29.17

Pfizer Inc Stock (PFE) Company Profile

Name
Nome
Pfizer Inc
Name
Telefono
(212) 733-2323
Name
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Dipendente
81,000
Name
Cinguettio
@Pfizer
Name
Prossima data di guadagno
2025-02-04
Name
Ultimi documenti SEC
Name
PFE's Discussions on Twitter

Confronta PFE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.85 140.38B 63.83B 10.77B 12.44B 1.8799
Drug Manufacturers - General icon
LLY
Lilly Eli Co
799.57 725.20B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
191.88 466.54B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
231.39 409.95B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
131.34 255.13B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.62 215.61B 63.43B 16.42B 14.72B 6.4861

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2024-12-10 Ripresa BofA Securities Neutral
2024-11-15 Iniziato Wolfe Research Underperform
2024-10-25 Ripresa Citigroup Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-08-07 Aggiornamento Daiwa Securities Neutral → Outperform
2024-03-22 Downgrade Argus Buy → Hold
2024-02-23 Iniziato Guggenheim Buy
2024-01-04 Downgrade TD Cowen Outperform → Market Perform
2023-10-20 Ripresa UBS Neutral
2023-10-16 Aggiornamento Jefferies Hold → Buy
2023-07-17 Reiterato JP Morgan Neutral
2023-07-14 Iniziato HSBC Securities Buy
2023-06-29 Downgrade Credit Suisse Outperform → Neutral
2023-05-11 Downgrade Daiwa Securities Outperform → Neutral
2023-03-06 Iniziato Jefferies Hold
2023-02-07 Aggiornamento Daiwa Securities Neutral → Outperform
2023-01-26 Downgrade UBS Buy → Neutral
2023-01-17 Downgrade Wells Fargo Overweight → Equal Weight
2023-01-04 Downgrade BofA Securities Buy → Neutral
2022-12-13 Aggiornamento Goldman Neutral → Buy
2022-11-18 Iniziato Credit Suisse Outperform
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2022-01-05 Aggiornamento BofA Securities Neutral → Buy
2022-01-03 Reiterato Bernstein Mkt Perform
2021-12-20 Reiterato Cowen Outperform
2021-12-17 Iniziato Goldman Neutral
2021-12-13 Aggiornamento UBS Neutral → Buy
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-07-27 Ripresa Truist Buy
2021-05-06 Downgrade Mizuho Buy → Neutral
2021-04-07 Ripresa RBC Capital Mkts Sector Perform
2021-02-04 Aggiornamento DZ Bank Hold → Buy
2020-12-16 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-11-19 Ripresa Goldman Neutral
2020-11-10 Ripresa Bernstein Mkt Perform
2020-10-12 Downgrade Atlantic Equities Overweight → Neutral
2020-09-29 Iniziato Berenberg Hold
2020-06-16 Iniziato SVB Leerink Mkt Perform
2020-02-27 Iniziato Barclays Equal Weight
2020-02-27 Aggiornamento Standpoint Research Hold → Buy
2020-02-06 Iniziato Mizuho Buy
2020-01-07 Iniziato RBC Capital Mkts Outperform
2019-10-17 Ripresa BofA/Merrill Neutral
2019-07-30 Downgrade BofA/Merrill Buy → Neutral
2019-07-30 Downgrade Morgan Stanley Overweight → Equal-Weight
2019-06-04 Ripresa Morgan Stanley Overweight
2019-02-20 Ripresa Citigroup Neutral
2019-01-31 Aggiornamento Argus Hold → Buy
2019-01-31 Aggiornamento Credit Suisse Neutral → Outperform
2019-01-23 Downgrade UBS Buy → Neutral
2018-12-11 Downgrade JP Morgan Overweight → Neutral
2018-11-01 Downgrade BMO Capital Markets Outperform → Market Perform
Mostra tutto

Pfizer Inc Borsa (PFE) Ultime notizie

pulisher
Oct 21, 2025

Does the Recent 3% Gain Signal a Turning Point for Pfizer Shares? - simplywall.st

Oct 21, 2025
pulisher
Oct 21, 2025

mRNA Therapeutics and Global Markets to 2030, Profiles of Leading CompaniesModerna, Pfizer, BioNTech, Merck, and SanofiResearchAndMarkets.com - The AI Journal

Oct 21, 2025
pulisher
Oct 21, 2025

Pfizer Canada Announces Health Canada Approval of ABRYSVO® for Adults 18+ - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

2 Mega-Dividend Stocks With Yields As High As 7% - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

Pfizer (PFE) Receives a Hold from Wells Fargo - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Relay Therapeutics (RLAY) - The Globe and Mail

Oct 21, 2025
pulisher
Oct 21, 2025

Pfizer's Phase 3 Success and GSK's Rollout Expansion Spark Momentum in the Global Malaria Vaccine Market - openPR.com

Oct 21, 2025
pulisher
Oct 20, 2025

Lobbying Update: $2,730,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative

Oct 20, 2025
pulisher
Oct 20, 2025

What analyst consensus implies for Pfizer Inc. (PFE) stockWeekly Profit Report & Capital Efficient Trade Techniques - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Will Pfizer Inc. (Common Stock) (PFEB) stock deliver stable dividends2025 Analyst Calls & Accurate Entry and Exit Point Alerts - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

How Pfizer Inc. stock performs in volatility spikesJuly 2025 Retail & Technical Pattern Based Buy Signals - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

Endometriosis Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Ferring Pharma, AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharma - Barchart.com

Oct 20, 2025
pulisher
Oct 20, 2025

Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider - GlobeNewswire Inc.

Oct 20, 2025
pulisher
Oct 20, 2025

Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Canc - GuruFocus

Oct 20, 2025
pulisher
Oct 20, 2025

PFIZER INC : JP Morgan sticks Neutral - MarketScreener

Oct 20, 2025
pulisher
Oct 19, 2025

Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq

Oct 19, 2025
pulisher
Oct 19, 2025

Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus

Oct 19, 2025
pulisher
Oct 19, 2025

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech

Oct 19, 2025
pulisher
Oct 19, 2025

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer

Oct 19, 2025
pulisher
Oct 19, 2025

Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener

Oct 19, 2025
pulisher
Oct 19, 2025

40.3% lower risk of death — XTANDI + leuprolide raises 8‑yr OS to 78.9% in nmHSPC (Pfizer) - Stock Titan

Oct 19, 2025
pulisher
Oct 19, 2025

Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener

Oct 19, 2025
pulisher
Oct 19, 2025

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire

Oct 19, 2025
pulisher
Oct 18, 2025

Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS

Oct 18, 2025
pulisher
Oct 18, 2025

What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st

Oct 18, 2025
pulisher
Oct 18, 2025

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer

Oct 18, 2025
pulisher
Oct 18, 2025

Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener

Oct 18, 2025
pulisher
Oct 18, 2025

Will Pfizer Inc. (PFE) stock deliver compounding returns2025 Key Highlights & Reliable Price Action Trade Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda - MarketScreener

Oct 18, 2025
pulisher
Oct 18, 2025

Why Pfizer Inc. stock is considered a top pick2025 Top Decliners & Free Growth Oriented Trading Recommendations - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients - MarketScreener

Oct 18, 2025
pulisher
Oct 18, 2025

Will Pfizer Inc. stock attract ESG investorsJuly 2025 Sector Moves & Smart Money Movement Tracker - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Did Pfizer Overpay For Yet Another Acquisition? (NYSE:PFE) - Seeking Alpha

Oct 18, 2025
pulisher
Oct 18, 2025

Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential (NYSE:PFE) - Seeking Alpha

Oct 18, 2025
pulisher
Oct 18, 2025

How Pfizer Inc. (Common Stock) (PFEB) stock behaves under inflation pressure2025 Volatility Report & Low Risk Profit Maximizing Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Will Pfizer Inc. stock split again soonJuly 2025 PreEarnings & AI Enhanced Execution Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Energy Moves: Is Pfizer Inc. stock a buy on dipsJuly 2025 Sector Moves & AI Driven Price Forecasts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Can Pfizer Inc. (PFE) stock deliver strong annual returnsQuarterly Trade Review & Consistent Income Trade Recommendations - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Dow Update: Is Pfizer Inc. stock a good choice for value investors2025 Year in Review & Technical Pattern Based Signals - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Is Pfizer Inc. stock a good choice for value investorsMarket Sentiment Review & Weekly Watchlist of Top Performers - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

RSI Check: Is Pfizer Inc. stock positioned well for digital economy2025 Market Trends & Step-by-Step Trade Execution Guides - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Can Pfizer Inc. (PFE) stock retain market dominance2025 Key Lessons & Long-Term Growth Stock Strategies - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Why Pfizer Inc. stock attracts high net worth investorsPrice Action & Reliable Breakout Forecasts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Risk Off: Is Pfizer Inc. stock a good choice for value investors2025 Key Highlights & Entry Point Confirmation Signals - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer - TipRanks

Oct 17, 2025

Pfizer Inc Azioni (PFE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$124.08
price up icon 0.79%
drug_manufacturers_general SNY
$49.66
price down icon 0.14%
$301.14
price down icon 0.72%
drug_manufacturers_general NVO
$54.78
price down icon 1.72%
drug_manufacturers_general MRK
$87.62
price up icon 1.51%
Capitalizzazione:     |  Volume (24 ore):